biotech

biotech Articles

The novel coronavirus has wiped out trillions of dollars in global output with more than 1 million deaths worldwide in 2020. With cases rising rapidly in the United States and in Europe, more...
Amgen and Gilead released their most recent financial results after the closing bell on Wednesday.
Catabasis Pharmaceuticalswas absolutely devastated on Tuesday after the company announced top-line results from its late-stage study in muscular dystrophy.
The October 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
BioSig Technologies was absolutely crushed on Monday after the company announced that it would be halting its midstage coronavirus study.
Clinical-stage biopharmaceutical company Atea Pharma intends to price 11 million shares for and intial public offering valued up to more than $303 million.
BlondVax Pharma was absolutely crushed on Friday after the company reported late-stage results from its flu vaccine study. Needless to say, results obviously didn’t live up to expectations.
Gilead Sciences is the first company to cross the finish line for regulatory approval in the fight against the coronavirus.
Biogen reported better than expected third-quarter financial results with disappointing guidance before the markets opened on Wednesday.
Aptinyx shares soared on Tuesday after the company provided an update from its midstage study in post-traumatic stress disorder.
Are BioSpecific Technologies shareholders actually getting a good deal from the merger agreement with Endo International?
OraSure Technologies shares jumped to start off the week after the company announced an update from the FDA in regards to its COVID-19 test kit.
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well. After all, many investors missed the bulk of the recovery from March’s panic...
While other companies seem to be struggling with their coronavirus vaccines, Pfizer and BioNTech are just picking up speed. Pfizer’s CEO has provided an update on their COVID-19 vaccine.
Taiwan Liposome has enrolled its first subject for its coronavirus treatment that includes the controversial hydroxychloroquine.